Temporally Programmed CD8α+ DC Activation Enhances Combination Cancer Immunotherapy.

[1]  Yun-Ru Chen,et al.  Modulation of P2X4/P2X7/Pannexin-1 sensitivity to extracellular ATP via Ivermectin induces a non-apoptotic and inflammatory form of cancer cell death , 2015, Scientific Reports.

[2]  D. Longo,et al.  Out-of-Sequence Signal 3 Paralyzes Primary CD4(+) T-Cell-Dependent Immunity. , 2015, Immunity.

[3]  I. Melero,et al.  Evolving synergistic combinations of targeted immunotherapies to combat cancer , 2015, Nature Reviews Cancer.

[4]  L. Zitvogel,et al.  STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells. , 2015, Cancer research.

[5]  George E. Katibah,et al.  Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. , 2015, Cell reports.

[6]  L. Galluzzi,et al.  Combinatorial Strategies for the Induction of Immunogenic Cell Death , 2015, Front. Immunol..

[7]  D. Irvine,et al.  Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. , 2015, Cancer cell.

[8]  L. Rénia,et al.  Type I IFN signaling in CD8- DCs impairs Th1-dependent malaria immunity. , 2014, The Journal of clinical investigation.

[9]  S. Rosenberg,et al.  Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions , 2014, Clinical Cancer Research.

[10]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[11]  yang-xin fu,et al.  Type I interferon response and innate immune sensing of cancer. , 2013, Trends in immunology.

[12]  T. Lynch,et al.  Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  E. Mardis,et al.  Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting , 2012, Nature.

[14]  C. Sousa.  Faculty Opinions recommendation of Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. , 2011 .

[15]  R. Schreiber,et al.  Type I interferon is selectively required by dendritic cells for immune rejection of tumors , 2011, The Journal of experimental medicine.

[16]  K. Murphy,et al.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells , 2011, The Journal of experimental medicine.

[17]  M. Cragg,et al.  Interaction with FcγRIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody , 2011, The Journal of Immunology.

[18]  S. Loi,et al.  Anti–ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti–PD-1 or anti-CD137 mAb therapy , 2011, Proceedings of the National Academy of Sciences.

[19]  M. Greene,et al.  The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. , 2010, Cancer cell.

[20]  Andrew E. Parker,et al.  Targeting Toll-like receptors: emerging therapeutics? , 2010, Nature Reviews Drug Discovery.

[21]  C. Liu,et al.  IFN-α Enhances Peptide Vaccine-Induced CD8+ T Cell Numbers, Effector Function, and Antitumor Activity1 , 2009, The Journal of Immunology.

[22]  A. Dalgleish.  Cytokines in the genesis and treatment of cancer , 2007, British Journal of Cancer.

[23]  H. Kaufman,et al.  Combination Cytokine Therapy , 2007 .

[24]  G. Belz,et al.  Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity , 2006, Nature Immunology.

[25]  Dolca Thomas,et al.  Distinct roles of IL-12 and IL-15 in human natural killer cell activation by dendritic cells from secondary lymphoid organs. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[26]  R. Steinman,et al.  Activation of Natural Killer T Cells by -Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein , 2003 .

[27]  M. Bevan,et al.  Constitutive versus Activation-dependent Cross-Presentation of Immune Complexes by CD8+ and CD8− Dendritic Cells In Vivo , 2002, The Journal of experimental medicine.

[28]  N. Restifo,et al.  B16 as a Mouse Model for Human Melanoma , 2000, Current protocols in immunology.

[29]  K. Pang,et al.  Type I IFNs enhance the terminal differentiation of dendritic cells. , 1998, Journal of immunology.

[30]  A. Craiu,et al.  Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. , 1998, Journal of immunology.

[31]  B. Morgenstern,et al.  Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia. , 1982, Cancer research.